Ulcerative Colitis – Epidemiology – Epidemiology Dashboard
Clarivate Epidemiology’s coverage of ulcerative colitis (UC) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed prevalence and the diagnosed incidence of UC for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the mature markets and Europe and 10 years for the other countries we cover.
All forecast data are available on Clarivate’s Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Clarivate Epidemiology’s UC forecast answers the following questions:
- How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of UC and the number of new diagnoses of UC?
- In developing countries, what impact will economic growth and development have on the number of people living with a diagnosis of UC and the number of new diagnoses of UC?
- How will improvements in survival change the number of people living with a diagnosis of UC?
- Of all people diagnosed with UC, how many in each of the major mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of UC over the forecast period?
In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following UC subpopulations:
- Diagnosed prevalent cases.
- Diagnosed incident cases.
- Diagnosed prevalent cases by disease extent.
- Diagnosed prevalent cases by disease severity.
- Diagnosed prevalent cases by treatment scheme.
Note: Coverage may vary by country.
